Vanda Pharmaceuticals' Senior VP, General Counsel and Secretary Resigns
VNDA sits 84% above its 52-week low of $3.809 on light trading volume (0.4× avg).
Summary
Vanda Pharmaceuticals announced the resignation of Timothy Williams, its Senior Vice President, General Counsel, and Secretary, effective April 10, 2026.
Key Events · Executive and Board Changes · VNDA
-
Executive Resignation
Timothy Williams, Senior Vice President, General Counsel and Secretary, notified the company of his resignation.
-
Effective Date
The resignation is effective as of April 10, 2026.
-
Reason for Departure
Mr. Williams is departing to pursue other endeavors.
Analysis · VNDA · Life Sciences
The resignation of a Senior Vice President, General Counsel, and Secretary is an important event for a company, particularly one in the life sciences sector that often navigates complex regulatory and legal landscapes. While the stated reason is to 'pursue other endeavors,' the departure of a key executive can raise questions about leadership stability and future strategic direction, especially given the company's recent financial losses and regulatory setbacks mentioned in the last 10-K. Investors will likely monitor for any subsequent appointments or further executive changes.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.3% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.8M. The 52-week trading range was $3.81 to $9.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.